Apellis Pharmace SEC Filings

Apellis Pharmaceuticals’ Chief Scientific Officer Pascal Deschatelets reported multiple equity transactions tied to the closing of Biogen’s acquisition of the company. On the completion of Biogen’s tender offer and merger, 1,177,222 common shares were disposed of into the offer.

Each tendered share was exchanged for $41.00 in cash plus one contingent value right (CVR) with potential additional cash payments of up to an aggregate $4.00 per share upon specified milestones. Outstanding RSUs and stock options were cancelled or converted into cash-and-CVR rights based on their vesting terms and exercise prices, while certain underwater options were cancelled without consideration.

Apellis Pharmaceuticals director Gerald Chan reported disposing of his holdings in connection with the company’s sale to Biogen. On May 14, 2026, he disposed of multiple blocks of Apellis common stock, including 25,666 shares classified as a tender-offer disposition, leaving zero shares reported as directly owned.

The filing explains that Apellis agreed to be acquired by Biogen through a tender offer and merger. Each Apellis share tendered before the offer expired was exchanged for $41.00 in cash per share plus one contingent value right, or CVR. Each CVR can pay up to an aggregate of $4.00 in cash if specified milestones are achieved. Vested stock options with exercise prices below $41.00 were cancelled and converted into cash equal to the spread plus one CVR per underlying share, while options with exercise prices at or above $45.00 were cancelled without payment.

Apellis Pharmaceuticals’ chief technical officer Nur Nicholson reported multiple equity award changes tied to the company’s acquisition by Biogen. Common shares tendered in the offer were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 per share upon specified milestones. Restricted stock units (RSUs) were cancelled and replaced with rights to receive cash based on the offer price and one CVR per underlying share, continuing to vest over time but without performance conditions. Stock options were cancelled and, depending on their exercise price, converted into cash plus CVRs, CVRs only, or, for options with exercise prices at or above $45.00, cancelled without consideration.

Apellis Pharmaceuticals director Keli Walbert reported a series of dispositions tied to the company’s acquisition by Biogen. Under the merger agreement, Apellis shares tendered in the offer were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 in cash, subject to milestones and tax withholding. On the merger’s effective date, Walbert disposed of common stock both back to the issuer and pursuant to the tender offer, and all reported stock options with exercise prices below $41.00 were cancelled in exchange for cash based on the spread to the cash amount plus CVRs. Following these transactions, the filing shows no remaining directly held Apellis common shares or stock options for this reporting person.

Apellis Pharmaceuticals executive Mark Jeffrey DeLong reported multiple equity award changes tied to the company’s merger with Biogen. Common shares tendered before the merger were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 per share upon specified milestones.

Following completion of the tender offer, Biogen’s subsidiary merged into Apellis, making Apellis a wholly owned subsidiary. In connection with this, DeLong disposed of common stock and stock options back to the issuer or via the tender offer, and received new stock awards, including grants of 18,303, 36,606, 19,006 and 41,250 shares of common stock as compensation-related awards rather than open‑market purchases.

Apellis Pharmaceuticals director Stephanie Monaghan O'Brien reported multiple share and option dispositions tied to the closing of Biogen’s acquisition of Apellis. On May 14, 2026, Apellis became a wholly owned subsidiary of Biogen after a tender offer and follow-on merger.

According to the merger terms, each tendered share of Apellis common stock was exchanged for $41.00 in cash per share plus one contingent value right (CVR) that can pay up to an additional $4.00 in cash upon specified milestones. The Form 4 shows blocks of common shares, including some held indirectly through O'Brien’s spouse, disposed of in the tender offer and related issuer transactions.

Vested stock options with exercise prices below $41.00 were cancelled and converted into cash equal to the spread between the offer price and the exercise price, plus one CVR per underlying share. Options with exercise prices at or above $45.00 were cancelled without payment. After these transactions, the filing shows no remaining reported common stock or options for O'Brien.

Apellis Pharmaceuticals’ Chief People Officer Kelley Boucher reported multiple equity transactions tied to the completion of Apellis’s merger with a Biogen subsidiary. Common shares tendered before the offer expired were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that may pay up to an additional $4.00 in cash per share if specified milestones are met. Following the tender offer and subsequent merger effective at the filing of the certificate of merger on May 14, 2026, Apellis became a wholly owned subsidiary of Biogen. In connection with the merger, previously outstanding restricted stock units and vested stock options were cancelled and converted into rights to receive cash based on the $41.00 cash amount plus one CVR per underlying share, with vesting and “double-trigger” conditions generally preserved but with performance-based vesting removed. Boucher also received new awards of 30,146 and 15,073 shares of common stock as compensation grants, which she now holds directly, and all listed stock options were disposed of to the issuer.

Apellis Pharmaceuticals director Craig A. Wheeler exited his Apellis stake as part of the company’s merger with Biogen. On May 14, 2026, he disposed of common shares and cancelled vested stock options in transactions classified as dispositions to the issuer and tender-offer dispositions.

Under the merger terms, each Apellis common share was exchanged for $41.00 in cash plus one contingent value right, which may pay up to an additional $4.00 per share if specified milestones are met. Vested in-the-money options were cancelled for cash based on the excess of the cash amount over the exercise price, plus one contingent value right per underlying share. Following these transactions, Wheeler reported no remaining Apellis common stock or stock options.

Apellis Pharmaceuticals’ General Counsel, David O. Watson, reported multiple stock and option transactions tied to the company’s acquisition by Biogen. Common shares tendered in the offer were exchanged for $41.00 in cash per share plus one contingent value right (CVR) that can pay up to an additional $4.00 in cash if milestones are met. Several restricted stock unit awards were converted into the right to receive cash based on this cash amount and associated CVRs, with vesting tied to continued service. Vested stock options with lower exercise prices were cashed out for cash and CVRs, while higher‑priced options at or above $45.00 per share were cancelled without consideration. These actions are mechanical effects of the merger agreement rather than open‑market trading decisions.